Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...

Here's how to get your hands on the hottest clothing, shoes, and accessories launches of 2025, according to our PEOPLE Style ...

Lilly is projecting between $58 billion and $61 billion in sales, which is mostly higher than the $58.4 billion that analysts expected. In its press release, it didn't provide specific guidance ...

Shares of Eli Lilly & Co. were headed for their worst day ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

By Sara Ruberg Darrin Bell, a Pulitzer Prize-winning cartoonist ... Investigators connected Mr. Bell, 49, to an online account that had shared 134 files of child sex abuse, the Sacramento County ...

Pulitzer Prize-winning cartoonist Darrin Lawrence ... AI-generated — that detectives say the 49-year-old uploaded to an online account. Bell, a Northern California resident, was arrested ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...